Umeclidinium

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Umeclidinium
   1. Pharmacist Assessment Report
   2. Umeclidinium: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Umeclidinium: Known uses and market status in Australia

Summary

The TxGNN model has no candidate with a score of 0.99 or higher for Umeclidinium, so there is currently no new predicted indication. The drug’s recorded uses are listed below; no uses are recorded for this drug in the available data.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	0
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
none	none

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
none

Australia Market Information

Licence	Product	Dosage form	Status
10187E	Incruse Ellipta	Powder for oral inhalation in breath act	Valid

Safety Considerations

• Drug Interactions: 100 potential interactions were identified, and 20 are shown in the data compiled. All listed are Moderate severity, mainly additive anticholinergic effects with other antimuscarinic agents. Examples include:
  • Atropine, hyoscyamine, scopolamine
  • Glycopyrronium, aclidinium, trospium
  • Dicyclomine, clidinium, propantheline
  • Promethazine, chlorpheniramine
  • Prucalopride, eluxadoline
  • Inhaled human insulin
• Glaucoma: Anticholinergics can cause mydriasis and raise intraocular pressure. Umeclidinium labelling carries a warning for narrow-angle glaucoma, which is directly relevant to the glaucoma predictions.

Please refer to the TGA-approved Product Information (PI) for the full warnings and contraindications.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---